• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预测阿尔茨海默病纵向研究中的缺失生物标志物数据。

Predicting missing biomarker data in a longitudinal study of Alzheimer disease.

机构信息

Division of Epidemiology, University of California, Berkeley, USA.

出版信息

Neurology. 2012 May 1;78(18):1376-82. doi: 10.1212/WNL.0b013e318253d5b3. Epub 2012 Apr 4.

DOI:10.1212/WNL.0b013e318253d5b3
PMID:22491869
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3345787/
Abstract

OBJECTIVE

To investigate predictors of missing data in a longitudinal study of Alzheimer disease (AD).

METHODS

The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a clinic-based, multicenter, longitudinal study with blood, CSF, PET, and MRI scans repeatedly measured in 229 participants with normal cognition (NC), 397 with mild cognitive impairment (MCI), and 193 with mild AD during 2005-2007. We used univariate and multivariable logistic regression models to examine the associations between baseline demographic/clinical features and loss of biomarker follow-ups in ADNI.

RESULTS

CSF studies tended to recruit and retain patients with MCI with more AD-like features, including lower levels of baseline CSF Aβ(42). Depression was the major predictor for MCI dropouts, while family history of AD kept more patients with AD enrolled in PET and MRI studies. Poor cognitive performance was associated with loss of follow-up in most biomarker studies, even among NC participants. The presence of vascular risk factors seemed more critical than cognitive function for predicting dropouts in AD.

CONCLUSION

The missing data are not missing completely at random in ADNI and likely conditional on certain features in addition to cognitive function. Missing data predictors vary across biomarkers and even MCI and AD groups do not share the same missing data pattern. Understanding the missing data structure may help in the design of future longitudinal studies and clinical trials in AD.

摘要

目的

探讨阿尔茨海默病(AD)纵向研究中缺失数据的预测因素。

方法

阿尔茨海默病神经影像学倡议(ADNI)是一项基于临床的、多中心的纵向研究,在 2005-2007 年间,对 229 名认知正常(NC)、397 名轻度认知障碍(MCI)和 193 名轻度 AD 患者进行了血液、CSF、PET 和 MRI 扫描的重复测量。我们使用单变量和多变量逻辑回归模型来研究基线人口统计学/临床特征与 ADNI 中生物标志物随访丢失之间的关系。

结果

CSF 研究倾向于招募和保留具有更多 AD 样特征的 MCI 患者,包括基线 CSF Aβ(42)水平较低。抑郁是 MCI 患者脱落的主要预测因素,而 AD 的家族史使更多的 AD 患者参加了 PET 和 MRI 研究。认知表现较差与大多数生物标志物研究中的随访丢失相关,甚至在 NC 参与者中也是如此。血管危险因素的存在似乎比认知功能对 AD 患者的脱落更具预测性。

结论

ADNI 中的缺失数据不是完全随机缺失的,除了认知功能外,还可能与某些特征有关。缺失数据的预测因素因生物标志物而异,甚至 MCI 和 AD 组也没有相同的缺失数据模式。了解缺失数据结构可能有助于 AD 的未来纵向研究和临床试验的设计。

相似文献

1
Predicting missing biomarker data in a longitudinal study of Alzheimer disease.预测阿尔茨海默病纵向研究中的缺失生物标志物数据。
Neurology. 2012 May 1;78(18):1376-82. doi: 10.1212/WNL.0b013e318253d5b3. Epub 2012 Apr 4.
2
Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.阿尔茨海默病患者纵向血浆神经丝轻链与神经退行性变的关系。
JAMA Neurol. 2019 Jul 1;76(7):791-799. doi: 10.1001/jamaneurol.2019.0765.
3
Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition.ADNI 认知正常受试者的神经元损伤生物标志物与预后。
Acta Neuropathol Commun. 2014 Mar 6;2:26. doi: 10.1186/2051-5960-2-26.
4
Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline.轻度认知障碍和主观认知下降亚型中的生物标志物。
Brain Behav. 2017 Jul 28;7(9):e00776. doi: 10.1002/brb3.776. eCollection 2017 Sep.
5
Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.记忆门诊中伴有正常β-淀粉样蛋白的轻度认知障碍患者向痴呆的进展。
Alzheimers Res Ther. 2019 Dec 5;11(1):99. doi: 10.1186/s13195-019-0557-1.
6
Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.在一个回顾性的认知障碍大患者队列中测试 2018 年 NIA-AA 研究框架:从生物标志物到临床综合征。
Alzheimers Res Ther. 2019 Oct 15;11(1):84. doi: 10.1186/s13195-019-0543-7.
7
Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.载脂蛋白 E 基因型与阿尔茨海默病脑脊液生物标志物的诊断准确性。
JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.
8
Neuropsychological Testing Predicts Cerebrospinal Fluid Amyloid-β in Mild Cognitive Impairment.神经心理学测试可预测轻度认知障碍患者脑脊液中的淀粉样蛋白β。
J Alzheimers Dis. 2015;46(4):901-12. doi: 10.3233/JAD-142943.
9
Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.体重指数降低与 MCI 和轻度痴呆患者的阿尔茨海默病病理的脑脊液标志物有关。
Exp Gerontol. 2017 Dec 15;100:45-53. doi: 10.1016/j.exger.2017.10.013. Epub 2017 Oct 17.
10
Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.阿尔茨海默病进展中淀粉样蛋白和 tau 生物标志物的相互预测关系:一个经验模型。
J Neurosci. 2019 Sep 11;39(37):7428-7437. doi: 10.1523/JNEUROSCI.1056-19.2019. Epub 2019 Jul 26.

引用本文的文献

1
ReMiND: Recovery of missing neuroimaging using diffusion models with application to Alzheimer's disease.ReMiND:利用扩散模型恢复缺失的神经影像并应用于阿尔茨海默病
Imaging Neurosci (Camb). 2024 Oct 22;2. doi: 10.1162/imag_a_00323. eCollection 2024.
2
Definition and analysis of gray matter atrophy subtypes in mild cognitive impairment based on data-driven methods.基于数据驱动方法的轻度认知障碍中灰质萎缩亚型的定义与分析
Front Aging Neurosci. 2024 Jun 4;16:1328301. doi: 10.3389/fnagi.2024.1328301. eCollection 2024.
3
Improving Regression Analysis with Imputation in a Longitudinal Study of Alzheimer's Disease.在阿尔茨海默病纵向研究中通过插补法改进回归分析
J Alzheimers Dis. 2024;99(1):263-277. doi: 10.3233/JAD-231047.
4
Attrition from longitudinal ageing studies and performance across domains of cognitive functioning: an individual participant data meta-analysis.纵向衰老研究中的人员流失和认知功能各领域的表现:一项个体参与者数据荟萃分析。
BMJ Open. 2024 Mar 7;14(3):e079241. doi: 10.1136/bmjopen-2023-079241.
5
Exploratory correlation of the human structural connectome with non-MRI variables in Alzheimer's disease.阿尔茨海默病中人类结构连接组与非MRI变量的探索性相关性研究。
Alzheimers Dement (Amst). 2023 Dec 17;15(4):e12511. doi: 10.1002/dad2.12511. eCollection 2023 Oct-Dec.
6
Exploratory Correlation of The Human Structural Connectome with Non-MRI Variables in Alzheimer's Disease.阿尔茨海默病中人类结构连接组与非MRI变量的探索性相关性
bioRxiv. 2023 Nov 9:2023.06.30.547308. doi: 10.1101/2023.06.30.547308.
7
Robust estimation of dementia prevalence from two-phase surveys with non-responders via propensity score stratification.通过倾向评分分层,对有失访者的两阶段调查进行稳健的痴呆患病率估计。
BMC Med Res Methodol. 2023 May 27;23(1):130. doi: 10.1186/s12874-023-01954-0.
8
Retaining Participants in Longitudinal Studies of Alzheimer's Disease.在阿尔茨海默病纵向研究中留住参与者
J Alzheimers Dis. 2022;87(2):945-955. doi: 10.3233/JAD-215710.
9
Research Attitudes Questionnaire scores predict Alzheimer's disease clinical trial dropout.研究态度问卷评分可预测阿尔茨海默病临床试验的脱落率。
Clin Trials. 2021 Apr;18(2):237-244. doi: 10.1177/1740774520982315. Epub 2021 Jan 10.
10
Retention of Alzheimer Disease Research Participants.阿尔茨海默病研究参与者的保留。
Alzheimer Dis Assoc Disord. 2019 Oct-Dec;33(4):299-306. doi: 10.1097/WAD.0000000000000353.

本文引用的文献

1
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.阿尔茨海默病神经影像学倡议(ADNI):临床特征。
Neurology. 2010 Jan 19;74(3):201-9. doi: 10.1212/WNL.0b013e3181cb3e25. Epub 2009 Dec 30.
2
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI.AD 和 MCI 认知、功能和 FDG-PET 测量下降之间的关联。
Neurobiol Aging. 2011 Jul;32(7):1207-18. doi: 10.1016/j.neurobiolaging.2009.07.002. Epub 2009 Aug 5.
3
Missing data: a special challenge in aging research.缺失数据:衰老研究中的一项特殊挑战。
J Am Geriatr Soc. 2009 Apr;57(4):722-9. doi: 10.1111/j.1532-5415.2008.02168.x. Epub 2009 Feb 10.
4
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.阿尔茨海默病神经影像学倡议(ADNI):磁共振成像方法
J Magn Reson Imaging. 2008 Apr;27(4):685-91. doi: 10.1002/jmri.21049.
5
General cardiovascular risk profile for use in primary care: the Framingham Heart Study.用于初级保健的一般心血管风险概况:弗雷明汉心脏研究
Circulation. 2008 Feb 12;117(6):743-53. doi: 10.1161/CIRCULATIONAHA.107.699579. Epub 2008 Jan 22.
6
PENN biomarker core of the Alzheimer's disease Neuroimaging Initiative.阿尔茨海默病神经影像倡议组织的宾夕法尼亚生物标志物核心。
Neurosignals. 2008;16(1):19-23. doi: 10.1159/000109755. Epub 2007 Dec 5.
7
Cognitive function, gait speed decline, and comorbidities: the health, aging and body composition study.认知功能、步速下降与共病:健康、衰老与身体成分研究
J Gerontol A Biol Sci Med Sci. 2007 Aug;62(8):844-50. doi: 10.1093/gerona/62.8.844.
8
What do people at risk for Alzheimer disease think about surrogate consent for research?有患阿尔茨海默病风险的人对研究中的替代同意是怎么看的?
Neurology. 2005 Nov 8;65(9):1395-401. doi: 10.1212/01.wnl.0000183144.61428.73.
9
Surrogate decision-making and related issues.替代决策制定及相关问题。
Alzheimer Dis Assoc Disord. 2003 Apr-Jun;17 Suppl 1:S12-6. doi: 10.1097/00002093-200304001-00003.
10
Impaired decision-making ability in subjects with Alzheimer's disease and willingness to participate in research.阿尔茨海默病患者决策能力受损及参与研究的意愿
Am J Psychiatry. 2002 May;159(5):797-802. doi: 10.1176/appi.ajp.159.5.797.